Pharmacogenomics in the Oceania Region: Precision Medicine Challenges

Somogyi, Andrew A. (2018). "Pharmacogenomics in the Oceania Region: Precision Medicine Challenges". Proceedings for Annual Meeting of the Japanese Pharmacological Society. WCP2018 (0): SY48-1. doi:10.1254/jpssuppl.WCP2018.0_SY48-1. ISSN 2435-4953.

Abstract: Oceania comprises the large islands of Australia, New Zealand and Papua New Guinea (PNG) and a very large number of islands comprising Melanesia, Micronesia and Polynesia. There are few pharmacogenomic studies and results cannot be readily predicted from one region to another. For example, CYP2C19 genotypic poor metabolisers (*2,*3) comprise almost 70% of the Melanesians in Vanuatu, less than 10% in Maori populations and less than 5% in Aboriginal Australians, and in the latter population, the gain of function *17 results in 17% rapid metabolisers, half that of Caucasians. Such large differences are in contrast to CYP2D6 poor metabolisers (*4,*5) which comprise less than 1% in most of the regions studied.

Extra details:

MAG: 3084319102
OpenAlex: W3084319102